109 related articles for article (PubMed ID: 19902516)
1. Homozygous familial hypercholesterolemia: long term clinical course and plasma exchange therapy for two individual patients and review of the literature.
Beigel R; Beigel Y
J Clin Apher; 2009; 24(6):219-24. PubMed ID: 19902516
[TBL] [Abstract][Full Text] [Related]
2. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
Jensen HK
Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
[TBL] [Abstract][Full Text] [Related]
3. Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia.
Stefanutti C; Di Giacomo S; Vivenzio A; Isacchi GC; Masella R; Caprari P; Varì R; Tarzia A; Mosiello A; Cantafora A
Clin Sci (Lond); 2001 Feb; 100(2):191-8. PubMed ID: 11171288
[TBL] [Abstract][Full Text] [Related]
4. [LDL oxidation in homozygous familial hypercholesterolemia: effects of selective LDL-apheresis treatment].
Napoli C; Postiglione A; Scarpato N; Corso G; Ambrosio G; Condorelli M; Mancini M; Chiariello M
Cardiologia; 1996 May; 41(5):435-9. PubMed ID: 8767632
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of LDL apheresis in patients with severe hypercholesterolemia.
Sachais BS; Katz J; Ross J; Rader DJ
J Clin Apher; 2005 Dec; 20(4):252-5. PubMed ID: 15880364
[TBL] [Abstract][Full Text] [Related]
6. [Extracorporeal elimination of LDL-cholesterol in the treatment of hypercholesterolemia: indications and methods].
Bláha V; Havel E; Zadák Z; Pidrman V; Bláha M; Kalinová M
Vnitr Lek; 1995 Oct; 41(10):724-9. PubMed ID: 8578708
[TBL] [Abstract][Full Text] [Related]
7. Low density lipoprotein apheresis in pediatric patients with homozygous familial hypercholesterolemia.
Coker M; Ucar SK; Simsek DG; Darcan S; Bak M; Can S
Ther Apher Dial; 2009 Apr; 13(2):121-8. PubMed ID: 19379151
[TBL] [Abstract][Full Text] [Related]
8. Treatment of homozygous familial hypercholesterolemia by plasma exchange and LDL-apheresis.
Palcoux JB; Meyer M; Jouanel P; Tridon A; Vanlieferinghen P; Carla H; Malpuech G
Transfus Sci; 1993 Oct; 14(4):423-7. PubMed ID: 10146648
[TBL] [Abstract][Full Text] [Related]
9. Regression of coronary atherosclerosis and amelioration of renal function during LDL-immunoadsorption therapy in a renal transplant recipient.
Jansen M; Gabriel H; Banyai S; Pidlich J; Weidinger F; Hörl WH; Derfler K
Wien Klin Wochenschr; 1996; 108(14):425-31. PubMed ID: 8784984
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia.
Hudgins LC; Kleinman B; Scheuer A; White S; Gordon BR
Am J Cardiol; 2008 Nov; 102(9):1199-204. PubMed ID: 18940291
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of LDL-receptor expression by LDL-immunoapheresis in patients with familial hypercholesterolemia.
Streicher J; Valent P; Schmidt H; Sengölge G; Wagner O; Strobl W; Hörl WH; Derfler K
J Investig Med; 1999 Sep; 47(8):378-87. PubMed ID: 10510590
[TBL] [Abstract][Full Text] [Related]
12. Apheresis technologies for prevention and regression of atherosclerosis: clinical results.
Bambauer R; Schneidewind JM; Latza R
ASAIO J; 1999; 45(5):403-7. PubMed ID: 10503615
[TBL] [Abstract][Full Text] [Related]
13. Early-onset plasmapheresis and LDL-apheresis provide better disease control for pediatric homozygous familial hypercholesterolemia than HMG-CoA reductase inhibitors and ameliorate atherosclerosis.
Dann EJ; Shamir R; Mashiach T; Shaoul R; Badian A; Stravets T; Kerzman Y; Finkelbaum S; Gaitini D; Lorber A; Bonstein L
Transfus Apher Sci; 2013 Oct; 49(2):268-77. PubMed ID: 23791799
[TBL] [Abstract][Full Text] [Related]
14. Liver transplantation in patients with homozygotic familial hypercholesterolemia previously treated by end-to-side portocaval shunt and ileal bypass.
López-Santamaria M; Migliazza L; Gamez M; Murcia J; Diaz-Gonzalez M; Camarena C; Hierro L; De la Vega A; Frauca E; Diaz M; Jara P; Tovar J
J Pediatr Surg; 2000 Apr; 35(4):630-3. PubMed ID: 10770402
[TBL] [Abstract][Full Text] [Related]
15. Plasmapheresis in familial hypercholesterolemia.
Thompson GR; Barbir M; Okabayashi K; Trayner I; Larkin S
Arteriosclerosis; 1989; 9(1 Suppl):I152-7. PubMed ID: 2912429
[TBL] [Abstract][Full Text] [Related]
16. Clinical applications of long-term LDL-apheresis on and beyond refractory hypercholesterolemia.
Mabuchi H; Higashikata T; Kawashiri MA
Transfus Apher Sci; 2004 Jun; 30(3):233-43. PubMed ID: 15172629
[TBL] [Abstract][Full Text] [Related]
17. Magnitude of HDL cholesterol variation after high-dose atorvastatin is genetically determined at the LDL receptor locus in patients with homozygous familial hypercholesterolemia.
Sposito AC; Gonbert S; Bruckert E; Atassi M; Beucler I; Amsellem S; Khallouf O; Benlian P; Turpin G
Arterioscler Thromb Vasc Biol; 2003 Nov; 23(11):2078-82. PubMed ID: 14512370
[TBL] [Abstract][Full Text] [Related]
18. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group.
Kitabatake A; Sato H; Hori M; Kamada T; Kubori S; Hoki N; Minamino T; Yamada M; Kato T
Clin Ther; 1994; 16(3):416-28. PubMed ID: 7923308
[TBL] [Abstract][Full Text] [Related]
19. Direct adsorption of lipoproteins (DALI) from whole blood: first long-term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolaemia.
Jansen M; Banyai S; Schmaldienst S; Goldammer A; Rohac M; Hörl WH; Derfler K
Wien Klin Wochenschr; 2000 Jan; 112(2):61-9. PubMed ID: 10703153
[TBL] [Abstract][Full Text] [Related]
20. [Non-dietary, non-pharmacological treatment of severe hypercholesterolemia].
Hansen PS; Sølling J; Knudsen TE; Faergeman O
Ugeskr Laeger; 1991 Jul; 153(29):2046-51. PubMed ID: 1858184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
